卢立康唑、拉康唑和 8 种对照剂对分子鉴定的镰刀菌属种的强效活性。
Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.
机构信息
Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.
出版信息
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00009-18. Print 2018 May.
Abstract
A collection of clinical ( = 47) and environmental ( = 79) isolates were tested against 10 antifungal drugs, including 2 novel imidazoles. Luliconazole and lanoconazole demonstrated very low geometric mean MIC values of 0.005 and 0.013 μg/ml, respectively, compared with 0.51 μg/ml for micafungin, 0.85 μg/ml for efinaconazole, 1.12 μg/ml for natamycin, 1.18 μg/ml for anidulafungin, 1.31 μg/ml for voriconazole, 1.35 μg/ml for caspofungin, 1.9 μg/ml for amphotericin B, and 4.08 μg/ml for itraconazole. Results show that these drugs are potential candidates for (topical) treatment of skin and nail infections due to species.
摘要
对 47 株临床分离株和 79 株环境分离株进行了 10 种抗真菌药物的测试，包括 2 种新型咪唑类药物。卢立康唑和拉诺康唑的几何平均 MIC 值分别为 0.005μg/ml 和 0.013μg/ml，而米卡芬净的 MIC 值为 0.51μg/ml，依氟康唑为 0.85μg/ml，那他霉素为 1.12μg/ml，阿尼芬净为 1.18μg/ml，伏立康唑为 1.31μg/ml，卡泊芬净为 1.35μg/ml，两性霉素 B 为 1.9μg/ml，伊曲康唑为 4.08μg/ml。结果表明，由于 种，这些药物可能成为（局部）治疗皮肤和指甲感染的候选药物。
相似文献
1
Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00009-18. Print 2018 May.
2
Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
Antimicrob Agents Chemother. 2012 Jan;56(1):352-7. doi: 10.1128/AAC.05414-11. Epub 2011 Nov 14.
3
Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02423-17. Print 2018 May.
4
Molecular identification, biofilm formation and antifungal susceptibility of Rhodotorula spp.
Mol Biol Rep. 2020 Nov;47(11):8903-8909. doi: 10.1007/s11033-020-05942-1. Epub 2020 Nov 1.
5
In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates.
Med Mycol. 2016 Oct 1;54(7):757-63. doi: 10.1093/mmy/myw016. Epub 2016 Apr 26.
6
Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
Arch Ophthalmol. 2007 Jun;125(6):789-93. doi: 10.1001/archopht.125.6.789.
7
Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00635-17. Print 2017 Nov.
8
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02045-16. Print 2017 Mar.
9
In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.
Antimicrob Agents Chemother. 2015 Dec;59(12):7818-22. doi: 10.1128/AAC.01733-15. Epub 2015 Sep 14.
10
[In vitro Antifungal Activity of Luliconazole against Trichophyton spp].
Med Mycol J. 2016;57(1):J1-6. doi: 10.3314/mmj.57.J1.
引用本文的文献
1
Antifungal Efficacy of Luliconazole-Loaded Nanostructured Lipid-Carrier Gel in an Animal Model of Dermatophytosis.
J Fungi (Basel). 2025 Apr 19;11(4):324. doi: 10.3390/jof11040324.
2
Luliconazole-loaded nanostructured lipid carrier: formulation, characterization, and in vitro antifungal evaluation against a panel of resistant fungal strains.
Sci Rep. 2024 Dec 28;14(1):30708. doi: 10.1038/s41598-024-79225-1.
3
antifungal activity of biosynthesized selenium nanoparticles using plant extracts and six comparators against clinical strains.
Curr Med Mycol. 2023 Dec;9(4):17-23. doi: 10.22034/CMM.2024.345189.1504.
4
Response of Fusarium oxysporum soil isolate to amphotericin B and fluconazole at the proteomic level.
Braz J Microbiol. 2024 Sep;55(3):2557-2568. doi: 10.1007/s42770-024-01417-8. Epub 2024 Jul 1.
5
First report of rhino-orbital mucormycosis caused by in a diabetic patient with COVID-19 in Iran and review of recent literature.
Curr Med Mycol. 2022 Jun;8(2):49-54. doi: 10.18502/cmm.8.2.10333.
6
Comparison of molecular and MALDI-TOF MS identification and antifungal susceptibility of clinical isolates in Southern China.
Front Microbiol. 2022 Sep 20;13:992582. doi: 10.3389/fmicb.2022.992582. eCollection 2022.
7
In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins Resistant Strains.
J Fungi (Basel). 2022 Jul 4;8(7):709. doi: 10.3390/jof8070709.
8
Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.
Mycoses. 2022 Jun;65(6):650-655. doi: 10.1111/myc.13442. Epub 2022 May 6.
9
A 23 bp Promoter Deletion Associated With Voriconazole Resistance in Clinical and Environmental Isolates of .
Front Microbiol. 2020 Mar 31;11:272. doi: 10.3389/fmicb.2020.00272. eCollection 2020.
10
Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates.
Mycopathologia. 2020 Apr;185(2):357-365. doi: 10.1007/s11046-020-00434-z. Epub 2020 Feb 28.
本文引用的文献
1
An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis.
J Fungi (Basel). 2017 May 5;3(2):20. doi: 10.3390/jof3020020.
2
In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex.
Mycoses. 2018 Feb;61(2):134-142. doi: 10.1111/myc.12716. Epub 2017 Nov 22.
3
Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00635-17. Print 2017 Nov.
4
Current antifungal treatment of fusariosis.
Int J Antimicrob Agents. 2018 Mar;51(3):326-332. doi: 10.1016/j.ijantimicag.2017.06.017. Epub 2017 Jul 10.
5
Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015.
Emerg Microbes Infect. 2016 Dec 7;5(12):e124. doi: 10.1038/emi.2016.126.
6
Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species.
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01671-16. Print 2017 Jan.
7
Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6916-6919. doi: 10.1128/AAC.01193-16. Print 2016 Nov.
8
In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method.
Diagn Microbiol Infect Dis. 2016 Aug;85(4):438-43. doi: 10.1016/j.diagmicrobio.2016.05.006. Epub 2016 May 12.
9
In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates.
Med Mycol. 2016 Oct 1;54(7):757-63. doi: 10.1093/mmy/myw016. Epub 2016 Apr 26.
10
Fusarium: Molecular Diversity and Intrinsic Drug Resistance.
PLoS Pathog. 2016 Apr 7;12(4):e1005464. doi: 10.1371/journal.ppat.1005464. eCollection 2016 Apr.
Zotero 插件